Louise Tallon responded, "I'm excited to join the Trinity Biotech team and look forward to contributing to its exciting vision to become a highly profitable organisation, intent on executing its development and launch of a next generation CGM device." This release includes statements that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Reform Act"), including but not limited to statements related to Trinity Biotech's cash position, fin ...

Commenting on the appointment, John Gillard, CEO of Trinity Biotech plc, said "We are delighted to welcome Louise, who brings extensive experience in transformation and growth within a dynamic environment. This skill set, combined with her extensive experience in the life sciences product commercialisation industry, will elevate the continued development of the organisation as we continue to deliver on our corporate strategy of delivering our comprehensive transformation plan and introducing our next genera ...

Core Insights - Trinity Biotech is advancing its next generation continuous glucose monitoring (CGM) solution towards market launch, having received regulatory approval for an initial European pre-pivotal trial [5][6] - The pre-pivotal trial is expected to begin imminently and be completed by the end of July, with data from this trial to inform a larger pivotal trial planned for 2025 [1][5] Company Overview - Trinity Biotech is a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors [6] - The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently entered the wearable biosensor industry [6] Technology and Innovation - The company has been working on innovations and improvements to its CGM technology since acquiring it earlier in the year [5] - The CGM solution and AI-driven health and wellness analytics technology are viewed as key long-term growth drivers for the company [5]

This pre-pivotal trial will begin imminently and is expected to be completed by the end of July. The study will assess the analytical performance of CGM technology enhancements implemented by Trinity Biotech. The data from this analytical performance assessment will be utilised to advance the technical optimization of the next generation CGM device ahead of the pivotal trial that is planned in 2025. Trinity Biotech President and Chief Executive Officer, Mr John Gillard stated "We believe our CGM solution an ...

About Trinity Biotech Management plans to host meetings with key stakeholders and potential partners as it works to advance the next generation of its recently acquired continuous glucose monitoring (CGM) biosensor technology. Interested parties are invited to reach out for more information by emailing Biosensors@trinitybiotech.com. To learn more about Trinity's CGM, please visit https://cgm.trinitybiotech.com LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trinitybiotech.com Co ...

DUBLIN, June 10, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the "Company"), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, announces that its senior management team plans to attend the 84th Scientific Sessions of the American Diabetes Association in Orlando Florida, taking place on June 21-24, 2024. About Trinity Biotech LifeSci Partners, LLC Eric Ribner (1)-646-751-4363 E-mail: investorrelations@trini ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bios ...

DUBLIN, June 03, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced the launch of its continuous glucose monitoring ("CGM") microsite - https://cgm.trinitybiotech.com. This website will be used to provide the Company's stakeholders with key insights into the Company's vision for the development of the next generation of its recently acquired CGM bio ...

Trinity Biotech plc (NASDAQ:TRIB) Q1 2024 Results Conference Call May 23, 2024 8:30 AM ET Company Participants Eric Ribner - Investor Relations John Gillard - Chief Executive Officer Des Fitzgerald - Chief Financial Officer Conference Call Participants Jim Sidoti - Sidoti & Company Operator Greetings, and welcome to the Trinity Biotech First Quarter 2024 Earnings Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Eric Ri ...

Core Insights - Trinity Biotech plc is on track to achieve approximately $20 million of annualized run-rate EBITDASO on annualized revenues of approximately $75 million by Q2 2025, driven by growth in existing businesses and operational efficiencies [1][2] - The company reported a strong sequential growth of 39% quarter-on-quarter in Point-of-Care revenues, primarily due to the successful rollout of TrinScreen HIV test production [1][2] - Operational efficiencies have led to a 3.6 percentage point increase in gross margin percentage quarter-on-quarter, with further improvements expected through 2024 and into early 2025 [1][2] Business Performance - Total revenues for Q1 2024 were $14.7 million, a slight decrease of 0.8% compared to $14.8 million in Q1 2023 [4][29] - The Point-of-Care portfolio generated revenues of $3.0 million for Q1 2024, reflecting a 38.5% increase from $2.2 million in Q1 2023 [4][6] - TrinScreen HIV sales reached $1.2 million in Q1 2024, with total orders for 2024 supply amounting to $6 million [2][4] Profitability Improvements - The net loss decreased from $5.5 million in Q4 2023 to $3.3 million in Q1 2024, marking a 40% improvement [2][12] - EBITDASO improved by 62% compared to Q4 2023, with expectations for further improvements through 2024 [2][12] - Selling, general and administrative expenses decreased to $7.5 million in Q1 2024 from $8.6 million in Q1 2023, driven by cost-saving initiatives [10][11] Operational Initiatives - The company is implementing a comprehensive transformation plan that includes optimizing supply chains and centralizing corporate services [3][5] - Significant progress has been made in offshoring manufacturing activities, with plans to cease main manufacturing at the Kansas City plant by the end of 2024 [5] - The company has engaged a consultancy for the design of its next-generation Continuous Glucose Monitoring system and is progressing towards a pre-pivotal clinical trial [5] Financial Position - Cash balance increased from $3.7 million at the end of Q4 2023 to $5.8 million at the end of Q1 2024 [19] - The company incurred investing cash outflows of $14.0 million in Q1 2024, primarily related to the acquisition of Waveform assets [19][31] - The renegotiation of the term loan resulted in a reduction of net financial expenses from $2.4 million in Q1 2023 to $0.2 million in Q1 2024 [12][14] Market Compliance - The company received a deficiency letter from Nasdaq regarding the market value of publicly held shares falling below the minimum requirement [21] - A staff determination letter indicated that the company did not regain compliance by the deadline, but it intends to request a hearing to avoid delisting [22][23]